Mind Medicine (MindMed) Inc.

Good morning, and welcome to the MindMed Medicine First Quarter 2022 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on Investor and Media section of MindMed's website at mindmed.co, and recording will be available after the call. For opening remarks, I would like to introduce Rob Barrow, CEO of MindMed. Please go ahead, sir.

Thank you, and good morning. I appreciate everyone joining us for our first quarter 2022 financial results in Corporate Update Conference Call. The press release reporting our financial results is available in the Investors and Media section of MyMed's website, and our quarterly report on Form 10-Q for the quarter ended March 31, 2022, will be filed today with the Securities and Exchange Commission. Joining me today is Dr. Daniel Carlin, our Chief Medical Officer, and Dr. Miri Halperin-Wernley, our Executive President. During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, financial projections and our future expectations, plans, partnerships, and prospects. These statements are subject to various risks that are described in the filings made with the SEC, including the most recent annual report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements, which are made as of today, May 16, 2022. MindMed disclaims any obligation to update such statements, even if management's views change. Before we dive into our program and corporate updates, I would like to reemphasize our ambition to transform the treatment of brain health disorders by delivering on the therapeutic potential of psychedelics and other novel targets. We are applying our pharmaceutical expertise to develop these innovative therapies with the aim of generating rapid and sustained improvement in patient outcomes with applicability to anxiety, addiction, and even autism. This is more important now than ever. The good news is that there has been a significant expansion in research to treat these conditions, and MindMed is leading the way in this effort. At MindMed, we are utilizing decades of research to accelerate and de-risk our three lead drug candidates, MM120, MM110, and MM402, along with other novel therapies. We are extremely pleased with the progress and transformational growth that continues to propel our business forward and position MindMed as a leader in developing novel therapies to treat brain health disorders. I will now turn the call over to our Chief Medical Officer, Dr. Daniel Carlin, to provide additional updates on each of our development programs.

Dan?